After The Stock Rose 4.06% Over The Week, Is Galectin Therapeutics Inc (NASDAQ: GALT) Still A Buy?
Galectin Therapeutics Inc (NASDAQ:GALT)’s traded shares stood at 0.41 million during the last session, with the company’s beta value hitting 0.62. At the close of